Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$1.71M | -$2.34M | -$5.57M |
| Net income | -$1.81M | -$2.60M | -$5.45M |
| EPS (diluted) | -$0.17 | -$0.23 | -$0.30 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $81.0K | -$3.96M | -$3.44M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $93.0K | $1.27M | $4.49M |
| Total assets | $965K | $5.77M | $6.54M |
| Total liabilities | $3.04M | $992K | — |
| Shareholders' equity | -$2.08M | $4.78M | $6.34M |
| Retained earnings | -$6.21M | -$8.81M | -$14.3M |
| Shares (wtd avg diluted) | 10.4M | 11.4M | 18.4M |
Every figure is extracted from Kairos Pharma, LTD.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.